Efficacy of ruxolitinib as salvage therapy for management of refractory chronic graft-versus-host disease (cGVHD).
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.